Clinical Trial Update: A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial investigating BTK inhibitor, PD-1, and Formustine as first-line therapy for primary CNS lymphoma (Phase 1/2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• BTK inhibitor
• Formustine
• PD-1 inhibitor

Snippet

Sponsor: Mingzhi Zhang | Conditions: Primary Central Nervous System Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN